ALNA. Blade ...The primary end pt the active arm ( drug arm ) was not that much better than the placebo arm . The secondary end pts were not statistically significant ...altho "trending towards " .
I don't know much about Hyperoxaluria but do know that diet is a big factor .
If the drug has promise then they should be able to sell Ex US rights to help fund continual development ...so I would want them to secure funding before I got involved .. I have only had a superficial look at the co .
Isn't greater than 20% reduction in 24 hr UOx what you're looking for ?
Market Data 
Markets 
AI
